Translocation of lysophosphatidic acid phosphatase in response to gonadotropin-releasing hormone to the plasma membrane in ovarian cancer cell.

OBJECTIVE Lysophosphatidic acid mediates proliferative and/or morphologic effects on multiple cell lineages, which include ovarian cancer cells. Lysophosphatidic acid hydrolysis limits the duration of lysophosphatidic acid's action. We examined hormonal translocation of lipid phosphate phosphatase type 3 to the plasma membrane in gonadotropin-releasing hormone-responsive ovarian cancers. STUDY DESIGN Ovarian cancers that were removed surgically and the ovarian cancer cell lines Caov-3 and SK-OV-3 were examined. Lipid phosphate phosphatase type 3 protein and activity in plasma membranes were assessed by immunohistochemical staining with lipid phosphate phosphatase type 3-specific antibodies and by the measurement of the conversion of exogenous [(3)H-oleoyl]lysophosphatidic acid to mono[(3)H-oleoyl]glycerol, respectively. RESULTS In ovarian cancers that were removed surgically, the cell surface staining and activity measurements indicated that a portion of the enzyme was localized to the plasma membrane. In Caov-3 cells and SK-OV-3 cells, lipid phosphate phosphatase type 3 protein was present both in the cytoplasm and at the plasma membrane. Treatment of the cells with a gonadotropin-releasing hormone agonist buserelin produced a rapid and progressive translocation of lipid phosphate phosphatase type 3 protein to the plasma membrane, with a concomitant loss of cytoplasmic staining. The enzyme activity in plasma membrane was also increased when the cell lines were exposed to the gonadotropin-releasing hormone agonist in intact cells before the assay of the cell membranes. CONCLUSION These findings support the presence of lipid phosphate phosphatase type 3 in plasma membrane of ovarian cancers and provide for the ability of agonists (such as gonadotropin-releasing hormone) to induce the translocation of lipid phosphate phosphatase type 3 to plasma membrane in ovarian cancer cells.

[1]  G. Mills,et al.  Lysophospholipids activate ovarian and breast cancer cells. , 1995, The Biochemical journal.

[2]  A. Schally,et al.  Growth-Inhibitory Actions of Analogues of Luteinizing Hormone Releasing Hormone on Tumor Cells , 1997, Trends in Endocrinology & Metabolism.

[3]  S. Rodenhuis,et al.  Growth factors in human ovarian cancer. , 1997, Cancer treatment reviews.

[4]  M. Key,et al.  Antigen retrieval in formalin-fixed, paraffin-embedded tissues: an enhancement method for immunohistochemical staining based on microwave oven heating of tissue sections. , 1991, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[5]  G. Mills,et al.  Critical role of lysophospholipids in the pathophysiology, diagnosis, and management of ovarian cancer. , 2002, Cancer treatment and research.

[6]  T. Fuseya,et al.  Signal transduction of GnRH receptor in the reproductive tract tumor. , 1996, Endocrine journal.

[7]  A. Morris,et al.  Role of phosphatidic acid phosphatase 2a in uptake of extracellular lipid phosphate mediators. , 2000, Biochimica et biophysica acta.

[8]  M. Gershengorn,et al.  Independent phosphatidylinositol synthesis in pituitary plasma membrane and endoplasmic reticulum , 1987, Nature.

[9]  O. Kranenburg,et al.  Lysophosphatidic acid: G-protein signalling and cellular responses. , 1997, Current opinion in cell biology.

[10]  M. Gershengorn,et al.  Measurement of lipid turnover in response to thyrotropin-releasing hormone. , 1987, Methods in enzymology.

[11]  S. Hsu,et al.  The use of antiavidin antibody and avidin-biotin-peroxidase complex in immunoperoxidase technics. , 1981, American journal of clinical pathology.

[12]  T. Furui,et al.  Gonadotropin‐releasing hormone receptor in gynecologic tumors. Frequent expression in adenocarcinoma histologic types , 1994, Cancer.

[13]  M. Kai,et al.  Cloning and Characterization of Two Human Isozymes of Mg2+-independent Phosphatidic Acid Phosphatase* , 1997, The Journal of Biological Chemistry.

[14]  M Markman,et al.  Lysophosphatidic acid as a potential biomarker for ovarian and other gynecologic cancers. , 1998, JAMA.

[15]  T. Hla,et al.  Lysophospholipids--Receptor Revelations , 2001, Science.

[16]  G. Mills,et al.  A putative new growth factor in ascitic fluid from ovarian cancer patients: identification, characterization, and mechanism of action. , 1988, Cancer research.

[17]  G. Carman,et al.  Lipid phosphate phosphohydrolase-1 degrades exogenous glycerolipid and sphingolipid phosphate esters , 1999 .

[18]  O. H. Lowry,et al.  Protein measurement with the Folin phenol reagent. , 1951, The Journal of biological chemistry.

[19]  A. Podtelejnikov,et al.  Endophilin I mediates synaptic vesicle formation by transfer of arachidonate to lysophosphatidic acid , 1999, Nature.

[20]  A. Morris,et al.  Human Type 2 Phosphatidic Acid Phosphohydrolases , 1998, The Journal of Biological Chemistry.

[21]  T. Tamaya,et al.  Evidence for tight coupling of gonadotropin-releasing hormone receptor to stimulated Fas ligand expression in reproductive tract tumors: possible mechanism for hormonal control of apoptotic cell death. , 1998, The Journal of clinical endocrinology and metabolism.

[22]  D. Brindley,et al.  Mammalian Lipid Phosphate Phosphohydrolases* , 1998, The Journal of Biological Chemistry.

[23]  G. Mills,et al.  A gonadotropin-releasing hormone-responsive phosphatase hydrolyses lysophosphatidic acid within the plasma membrane of ovarian cancer cells. , 2000, The Journal of clinical endocrinology and metabolism.

[24]  T. Morimoto,et al.  The Dri 42 Gene, Whose Expression Is Up-regulated during Epithelial Differentiation, Encodes a Novel Endoplasmic Reticulum Resident Transmembrane Protein* , 1996, The Journal of Biological Chemistry.

[25]  G. Mills,et al.  Characterization of an ovarian cancer activating factor in ascites from ovarian cancer patients. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

[26]  A. Morris,et al.  Sequential actions of phospholipase D and phosphatidic acid phosphohydrolase 2b generate diglyceride in mammalian cells. , 1999, Molecular biology of the cell.

[27]  G. Mills,et al.  Ascitic fluid from human ovarian cancer patients contains growth factors necessary for intraperitoneal growth of human ovarian adenocarcinoma cells. , 1990, The Journal of clinical investigation.

[28]  G. Mills,et al.  Peptide and lipid growth factors decrease cis-diamminedichloroplatinum-induced cell death in human ovarian cancer cells. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[29]  T. Tamaya,et al.  GnRH receptor and apoptotic signaling. , 2000, Vitamins and hormones.